Real‐world population pharmacokinetics of tezacaftor‐ivacaftor in children with cystic fibrosis: The SYM‐CF study
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70131 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Steffie E M Vonk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location University of Amsterdam, Department of Hospital Pharmacy & Clinical Pharmacology, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aims
The clinical effectiveness of tezacaftor‐ivacaftor in children with cystic fibrosis (cwCF) varies; some patients respond while others do not or have adverse effects. The pharmacokinetics (PK) of tezacaftor‐ivacaftor are inadequately published, especially in children. Knowledge of the PK in this cohort in relation to clinical outcomes may give further insight into the drug's exposure–response relationship and its associated interindividual variability. The aim of this study was to assess the real‐world PK of tezacaftor‐ivacaftor in cwCF.
Methods
A prospective, observational PK study was performed in cwCF using tezacaftor‐ivacaftor. PK samples were obtained by dried blood spots at home and during routine outpatient hospital visits. Population PK (popPK) models were created using nonlinear mixed‐effects modelling. Due to data scarcity, prior information from adolescent/adult PK models was required.
Results
The study involved 21 children (age 6–17 years, weight 24–70 kg). Novel popPK models were created for tezacaftor‐ivacaftor and its main metabolites. Variability in PK was explained by variation in body weight. The area under the curve of tezacaftor‐ivacaftor varied significantly within and across age groups, which corresponded to the reported area under the curve in the product information. Maximum concentration and elimination half‐lives closely matched adult reported values.
Conclusions
This is the first study to investigate the popPK of tezacaftor‐ivacaftor in cwCF. The established models can be used for more personalized dosing in children experiencing suboptimal efficacy, adverse effects, drug–drug interactions, or where adherence is a concern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amsterdam UMC location University of Amsterdam, Department of Hospital Pharmacy & Clinical Pharmacology, Amsterdam, The Netherlands.
- Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, Department of Pediatric Pulmonology and Allergy, Amsterdam, The Netherlands.
- Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Amsterdam UMC location University of Amsterdam, Department of Pulmonary Medicine, Amsterdam, The Netherlands.
- Amsterdam UMC location University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands.
ORCID-Profile: Steffie E M Vonk
Zitieren
APA
Vonk, S. E. M., Terheggen-Lagro, S. W. J., Haarman, E. G., Janssens, H. M., Maitland-van der Zee, A. H., Kemper, E. M., Mathôt, R. A. A., & Amsterdam Mucociliary Clearance Disease (AMCD) research group (2025). Real‐world population pharmacokinetics of tezacaftor‐ivacaftor in children with cystic fibrosis: The SYM‐CF study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70131
Vancouver
Vonk SEM, Terheggen-Lagro SWJ, Haarman EG, Janssens HM, Maitland-van der Zee AH, Kemper EM, et al. Real‐world population pharmacokinetics of tezacaftor‐ivacaftor in children with cystic fibrosis: The SYM‐CF study. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70131
BibTeX
@article{Vonk2025,
author = {Vonk, Steffie E M and Terheggen-Lagro, Suzanne W J and Haarman, Eric G and Janssens, Hettie M and Maitland-van der Zee, Anke-Hilse and Kemper, E Marleen and Mathôt, Ron A A and Amsterdam Mucociliary Clearance Disease (AMCD) research group, Amsterdam Mucociliary Clearance Disease (AMCD) research group},
title = {Real‐world population pharmacokinetics of tezacaftor‐ivacaftor in children with cystic fibrosis: The SYM‐CF study},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70131}
}
EUVIMED